Swedish neurotech startup Flow Neuroscience has secured FDA approval for the first brain stimulation device for home use in ...

In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved ...

With nearly 20 percent of U.S. adults affected by depression, the prevalence of this mental health condition drives many to explore relief from its most challenging symptoms. A recent study offers ...

While most tDCS devices have limitations in precise stimulation and show varying treatment effectiveness due to not considering individual brain structures, Neurophet has developed an AI-powered ...

The FDA has approved Flow, a prescription home-use cranial electrotherapy stimulation device, for treating moderate to severe ...

When added to stable selective serotonin reuptake inhibitors (SSRI) treatment, transcranial direct current stimulation (tDCS) was not superior to sham stimulation for major depressive disorder (MDD), ...

Depression affects approximately 280 million people all over the world, and disproportionately affects the female population — it is 50% more common in women than men. Treatments range from ...

Home-based transcranial direct current stimulation (tDCS) with real-time remote supervision was associated with significantly greater symptom improvement and higher clinical remission rates than sham ...

Unsupervised, at-home use of transcranial direct current stimulation (tDCS) was no better than a sham control for treating a major depressive episode, a randomized trial showed. The PSYLECT trial of ...